Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Amisulpride requires high doses because it struggles to cross into the brain, making long-acting injectables unviable. By engineering the molecule to penetrate the brain more readily, LB Pharmaceuticals reduced the required dose from 400 milligrams to 50 milligrams. This reduction enables both once-daily oral dosing and monthly injectable formulation.

Related Insights

Recognizing that severe myotonic dystrophy involves CNS impairment, Arthex deliberately invested in a lipid conjugation delivery system for its RNA therapeutic. This strategic choice was made specifically to cross the blood-brain barrier, enabling the treatment of both muscular and neurological symptoms of the disease.

Instead of relying on finding novel targets, a key strategy in neuropsychiatry is to revisit failed compounds that showed efficacy signals. Companies use modern chemistry and delivery to engineer solutions that separate efficacy from the historical liabilities that halted development, turning past failures into new opportunities.

Advanced cell therapy isn't just about replacing lost cells. Transplanted, genetically engineered cells can be programmed to produce and secrete therapeutics locally. This turns them into a delivery platform that solves the critical challenge of the blood-brain barrier for large molecules.

The historical difficulty of delivering biologics to the brain is being addressed by novel "brain shuttle" technologies. These platforms, which facilitate transport across the blood-brain barrier, are enabling new enzyme replacement therapies and even AAV-delivered biologics for CNS diseases like leukodystrophies.

The benzamide chemical class offers a unique mechanism by suppressing dopamine or triggering its release based on dosage. LB Pharmaceuticals utilizes this dose-dependent trait to address excessive dopamine in schizophrenia as well as dopamine deficits in depressive disorders using a single molecular foundation.

The success of the IDH inhibitor vorasidenib in glioma was driven by its specific design for blood-brain barrier (BBB) penetration. This contrasts with its predecessor, which failed in brain tumors due to poor CNS penetration, highlighting that BBB is a critical design consideration for neuro-oncology drugs.

Actuate’s drug was designed to be highly lipophilic (fat-soluble) to cross the blood-brain barrier for CNS treatment. This same property proved crucial for its success in oncology, as it allows the drug to easily penetrate cancer cell membranes and reach the nucleus.

New drug formulations, like those for HIV prevention or cholesterol, create an internal depot that releases medicine over months. This dramatically improves efficacy by solving the massive problem of patient non-adherence to daily pills, representing a major shift in managing chronic conditions.

The challenge of getting drugs into the brain is being solved, as proven by Denali's recent FDA approval for a drug using its BBB shuttle for Hunter disease. This, combined with Roche's promising Alzheimer's data with a similar technology, provides hard evidence that these platforms work, driving significant M&A and investment activity.

Voyager's ALPL-based blood-brain barrier shuttle offers a different pharmacokinetic profile than transferrin receptor shuttles. While delivering a lower initial peak concentration (Cmax), it provides a much longer half-life. This steady, sustained exposure is optimal for therapies that require constant pathway blockage, highlighting a key strategic trade-off in delivery system design.